Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Queensland Health
Medtronic
US Department of Justice
Dow
Fuji
Chinese Patent Office
Farmers Insurance

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206485

« Back to Dashboard

NDA 206485 describes MAGNESIUM SULFATE IN PLASTIC CONTAINER, which is a drug marketed by Fresenius Kabi Usa, Hospira, and Hq Spclt Pharma, and is included in three NDAs. It is available from four suppliers. Additional details are available on the MAGNESIUM SULFATE IN PLASTIC CONTAINER profile page.

The generic ingredient in MAGNESIUM SULFATE IN PLASTIC CONTAINER is magnesium sulfate. There are one hundred and thirty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the magnesium sulfate profile page.
Summary for 206485
Tradename:MAGNESIUM SULFATE IN PLASTIC CONTAINER
Applicant:Fresenius Kabi Usa
Ingredient:magnesium sulfate
Patents:0
Therapeutic Class:Therapeutic Nutrients/Minerals/Electrolytes
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206485
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 206485 ANDA Fresenius Kabi USA, LLC 63323-106 N 63323-106-26
MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 206485 ANDA Fresenius Kabi USA, LLC 63323-106 N 63323-106-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength4GM/100ML (40MG/ML)
Approval Date:Mar 15, 2016TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength4GM/50ML (80MG/ML)
Approval Date:Mar 15, 2016TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/50ML (40MG/ML)
Approval Date:Mar 15, 2016TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Baxter
Citi
Cerilliant
Covington
Teva
Dow
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.